A Phase 1 study of GRN163L (Imetelstat, IND# 170891, NSC# 754228) in combination with fludarabine and cytarabine for patients with acute myeloid leukemia that is in second or greater relapse or that is refractory to relapse therapy; myelodysplastic syndrome or juvenile myelomonocytic leukemia in first or greater relapse or is refractory to relapse therapy
| Protocol No. | PHO-COG-PEPN2312 | Scope | National |
|---|---|---|---|
| Principal Investigator | Weiss, Brian | Treatment Type | Treatment |
| Age Group | Children | Phase | Phase I |
